Jane Street’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.14M Sell
36,900
-31,400
-46% -$776K ﹤0.01% 6258
2026
Q1
$1.48M Sell
68,300
-6,600
-9% -$143K ﹤0.01% 5681
2025
Q4
$1.78M Sell
74,900
-19,000
-20% -$388K ﹤0.01% 5026
2025
Q3
$1.28M Buy
93,900
+10,400
+12% +$108K ﹤0.01% 5803
2025
Q2
$680K Buy
+83,500
New +$713K ﹤0.01% 6361
2024
Q2
Sell
-17,100
Closed -$323K 10048
2024
Q1
$323K Sell
17,100
-23,400
-58% -$405K ﹤0.01% 7442
2023
Q4
$774K Sell
40,500
-113,800
-74% -$1.82M ﹤0.01% 6031
2023
Q3
$2.77M Buy
+154,300
New +$3.1M ﹤0.01% 3497
2023
Q2
Sell
-30,100
Closed -$549K 9428
2023
Q1
$549K Buy
+30,100
New +$575K ﹤0.01% 6177
2022
Q4
Sell
-31,100
Closed -$814K 9962
2022
Q3
$814K Buy
31,100
+20,100
+183% +$532K ﹤0.01% 5807
2022
Q2
$279K Buy
+11,000
New +$269K ﹤0.01% 7729
2020
Q4
Sell
-16,400
Closed -$281K 7999
2020
Q3
$281K Sell
16,400
-2,300
-12% -$51.4K ﹤0.01% 5970
2020
Q2
$463K Buy
+18,700
New +$505K ﹤0.01% 5195

Other funds holding RCUS

Jane Street's RCUS Position: Q2 2026 in Review

Jane Street sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 107,979 shares — an estimated $2.67M sold.

Jane Street first reported a position in RCUS in Q4 2018 and held it in 23 quarters. The position peaked at $6.33M in Q4 2023. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Jane Street reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 107,979 Arcus Biosciences shares in Q2 2026, an estimated $2.67M.
  • Jane Street first reported a position in Arcus Biosciences in Q4 2018 and held it in 23 quarters.
  • Jane Street's Arcus Biosciences position peaked at $6.33M in Q4 2023.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.